Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
What they do
Unlearn.AI uses generative artificial intelligence to create TwinRCTs, which are randomized controlled trials utilizing digital twin cohorts. Pharmaceutical sponsors use these digital twins to reduce control group sizes, accelerate enrollment, and increase trial power.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Clinical trial design
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2017
- Total funding
- $130M raised
Notable investors: Altimeter Capital, Insight Partners, Radical Ventures, 8VC.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Decentralized and adaptive trial designs move from pilot to default in biotech development plans
Dr. Dereck Mush, MD, MBA
Inside SURPASS: ARPA-H's Bid to Redesign Clinical Trials
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA